Last week we announced the appointment of Alexander M. Gold, MD, to our Board of Directors. Dr. Gold brings over 20 years of experience leading the development, approval, and commercialization of new therapies. $MLYS
Mineralys Therapeutics, Inc.’s Post
More Relevant Posts
-
Antibody Engineering and Therapeutics 2023 is off to a great start! Don't forget to stop by Booth 508 to learn more about how Wheeler Bio, Inc. and Alloy Therapeutics, Inc. are aligning Discovery and CMC services through our new Phase™ preferred service offering. This is just the latest step we are taking to further reduce the time from Discovery to CMC clinical supply. See you soon! #AET #antibodytherapeutics #PortableCMC
Meet Us at Booth #508
https://wheelerbio.com
To view or add a comment, sign in
-
This isn't your typical drug sponsor + CDMO story. CTMC's Jason Bock says you shouldn't even classify his company as a CDMO. He's not wrong. On #BusinessOfBiotech, Thomas Leitch of KSQ Therapeutics, Inc. and Jason share their partnership story. "Our platform led us to some unique and very promising targets. But as as you alluded to earlier, Matt, having a target is not the same thing as having a therapy. And having a therapy is not the same thing as delivering a patient outcome. And our partnership with CTMC has really helped us accelerate those leads for targeted therapy to uninterrupted supply and and ultimately patient outcomes." Tom Leitch, CTO at KSQ Therapeutics. "And so, because we were running these studies already with MD Anderson - we've done many of these studies - we've got all of those logistics worked out. And so for our partners, they don't have to bother with any of it, we coordinate directly within the MD Anderson clinic. When they have a patient, we work out that we make sure we have a slot and we manufacture that product and then keep them informed and get that product back to the clinicians to infuse into the patients. And so, partners have full visibility into what's going on." Jason Bock, CEO, CTMC+. Thank you, Matthew Pillar and Bioprocess Online, for sitting down with Jason and Tom to hear the story of this exciting partnership. #biotech #celltherapy #TILtherapy #endcancer
THE BUSINESS OF BIOTECH
bioprocessonline.com
To view or add a comment, sign in
-
With new trends and policy implementations in 2024, #pharma executives are strategically and optimistically approaching the year ahead. At #JPM24, CEO Mark Litton, Ph.D. shared his thoughts with Meagan Parrish on how Athira is adapting to these new policies, including the #IRA. Read his thoughts in the new PharmaVoice trend piece here: https://bit.ly/3S0nVPP
Pharma execs sound off on trends and policies they’re tracking in 2024
pharmavoice.com
To view or add a comment, sign in
-
Theialife will be delighted to meet global investors next week at the Jefferies London Healthcare Conference. Theialife is a disruptive clinical stage biotech #ophthalmology company with a rich clinical pipeline of innovative therapies. We are proud to introduce our breakthrough oral drug (7MX) to prevent high Myopia (worlds largest medical unmet need) - Over 1200 children treated in Denmark - Post phase-2 & 12 years of clinical usage, we are phase-3 ready - 20 years of IP remaining. Please message Sundeep Aurora or Dr. Klaus Trier if you would like to meet, or email - neha.aurora@theialife.com Tommy Erdei Ashwin Pai Gil Bar-Nahum, PhD Michael Dodds Simone Botti Inkef Clara Campàs Moya Asabys Partners Lundbeckfonden / Lundbeck Foundation Hitachi Ventures Kurt Soost, CFA Pablo Cironi Michael Margolis Fiona MacLaughlin Naveed Siddiqi Caixa Capital Risc Novo Holdings Varun Gupta, PhD Wellington Partners Johnson & Johnson Simone Fishburn #biotech #innovation #novel #JefferiesHealthcare #investmentopportunities #venturecapital #investment #pharmaceutical #medicalinnovation #myopia #myopiacontrol
To view or add a comment, sign in
-
-
Theialife will be delighted to meet global investors next week at the Jefferies London Healthcare Conference. Theialife is a disruptive clinical stage biotech #ophthalmology company with a rich clinical pipeline of innovative therapies. Theialife is proud to introduce its breakthrough oral drug (7MX) to prevent high Myopia (worlds largest medical unmet need) - Over 1200 children treated in Denmark - Post phase-2 & 12 years of clinical usage, we are phase-3 ready - 20 years of IP remaining. Please message Sundeep Aurora or Dr. Klaus Trier if you would like to meet, or email - neha.aurora@theialife.com Tommy Erdei Ashwin Pai Gil Bar-Nahum, PhD Michael Dodds Simone Botti Inkef Clara Campàs Moya Asabys Partners Lundbeckfonden / Lundbeck Foundation Hitachi Ventures Kurt Soost, CFA Pablo Cironi Michael Buchanan Michael Margolis Fiona MacLaughlin Naveed Siddiqi Caixa Capital Risc Novo Holdings Varun Gupta, PhD Wellington Partners Johnson & Johnson Simone Fishburn #JefferiesHealthcare #investmentopportunities #venturecapital #biotech #innovation #novel #investment #pharmaceutical #medicalinnovation #myopia #myopiacontrol
To view or add a comment, sign in
-
-
Day 2 of the high-profile #JPMhealthcare Conference featured several major announcements and deals. - Eli Lilly's CEO David Ricks shared that the pharma giant is "open for business" on external innovation, coming off the successful launch of its weight loss drug Mounjaro. Ricks highlighted Lilly's willingness to partner amidst its solid in-house pipeline progress. - On the investment side, SR One CEO Dr. Simeon George noted the VC firm is tracking psychedelic medicine companies, but waiting for more maturation and rollout data before backing top players. George specifically mentioned J&J's SPRAVATO for depression as demonstrating early promise. - GlaxoSmithKline also grabbed attention at JPM, revealing plans to acquire Aiolos Bio, developer of a phase 2-ready autoimmune and inflammatory disease drug, for $1.4 billion total. The sizable buyout demonstrates pharma's continued appetite for next-gen biotech platforms and drug candidates, even amidst market uncertainty. Let's see what Day 3 brings!!! #jpm2024 #sanfrancisco
To view or add a comment, sign in
-
LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> Novartis shareholders vote in favor of Sandoz spinoff: Novartis’ Sandoz spinoff is right on track following a shareholder vote in favor of a full separation on Friday. The generics and biosimilars unit is expected to become independent on or around Oct. 4. That’s in line with what CEO Vas Narasimhan targeted when he first announced plans to spin out Sandoz last August, though talks of a potential spinout had been circulating for years before that. The company’s board of directors had already unanimously recommended the separation. Sandoz generated $9.1 billion in 2022 net sales. “Novartis is confident that the Spin-off is in the best interests of shareholders, creating a European champion and a global leader in Generics and Biosimilars, and a more focused Novartis,” the company said in a news release on Friday. Shortly after announcing the spinoff plans, Narasimhan laid out an ambitious agenda to transform Novartis into a top-five player in the US by 2027 with an emphasis on cell and gene therapy, radioligand therapy and RNA. The pharma giant changed the names of its business units earlier this month in anticipation of the spinoff, including its Institutes for BioMedical Research which will now be called just Biomedical Research. Sandoz CEO Richard Saynor wrote in a LinkedIn post on Friday that the shareholder vote “is a resounding vote of confidence in our vision for our future, as the world’s leading and most valued generics and biosimilars company.” #lucidquest #genetherapy #celltherapy
Novartis shareholders vote in favor of Sandoz spinoff, separation set for early October
https://endpts.com
To view or add a comment, sign in
-
Why AbbVie would pay $7 a share over a rival bidder's offer for ImmunoGen? Buckle up, it's a strategic tango with several potential motivations: Synergy Samba: - ELAHERE Tango: ImmunoGen's flagship, ELAHERE, is a platinum-resistant ovarian cancer darling. It's already tangoing with the market, but AbbVie can waltz it to Broadway with its global reach and commercial firepower. Think blockbuster potential, baby! - ADC Orchestra: ImmunoGen's next-gen ADCs are like Vivaldi on steroids. AbbVie's existing ADC platform needs some Bach, and these babies harmonize beautifully. Faster development, broader pipeline, a symphony of shareholder applause. Competitive Cha Cha: - Humira Blues: Humira, AbbVie's cash cow, is facing some fierce competition from biosimilar rivals. This ImmunoGen acquisition is like a salsa step into diversification, mitigating Humira's blues with oncology's hot rhythm. - #ADC Auction Heat: The ADC market is hotter than a flamenco dancer's castanets. AbbVie needed to outbid to avoid missing the beat. Consider it a strategic investment in future #growth, not just a bidding war trophy. Long-Term Mambo: - #Pipeline Paradise: ImmunoGen's early-stage pipeline is a treasure trove. Think pre-IPO tech startups with billion-dollar potential. AbbVie gets first dibs on these gems, a future mambo of innovation and returns. - Talent Tango: ImmunoGen's got some brilliant minds tangoing in their labs. AbbVie wants their expertise, their R&D mojo, to keep their #innovation engine humming. #Talent #acquisition, my friend, is a long-term cha-cha-cha. #investment #biotech #investor #market #business #PE #pharmaceutical #health 𝐈𝐟 𝐲𝐨𝐮 𝐚𝐫𝐞 𝐢𝐧𝐭𝐞𝐫𝐞𝐬𝐭𝐞𝐝 𝐢𝐧 𝐥𝐞𝐚𝐫𝐧𝐢𝐧𝐠 𝐦𝐨𝐫𝐞 𝐚𝐛𝐨𝐮𝐭 𝐭𝐡𝐞 𝐢𝐧𝐝𝐮𝐬𝐭𝐫𝐲, 𝐡𝐨𝐰 𝐭𝐨 𝐚𝐧𝐚𝐥𝐲𝐳𝐞 𝐭𝐡𝐞𝐬𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐚𝐧𝐝 𝐯𝐚𝐥𝐮𝐚𝐭𝐞 𝐭𝐡𝐞𝐦, 𝐩𝐥𝐞𝐚𝐬𝐞 𝐟𝐞𝐞𝐥 𝐟𝐫𝐞𝐞 𝐭𝐨 𝐫𝐞𝐚𝐜𝐡 𝐨𝐮𝐭 𝐭𝐨 𝐦𝐞 𝐨𝐫 Rohan Gidvani _________________________________________________________________________________ Have you enjoyed this? Recommend Repost ♻️ if you find it useful Follow me, hit the 🔔 Adrian Rubstein https://lnkd.in/dgpjDGES
AbbVie beat two rival bidders to acquire ImmunoGen for $10B, SEC filings show
https://endpts.com
To view or add a comment, sign in
-
📊 A new issue of our monthly “𝗙𝗖𝗙 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 & 𝗟𝗶𝗳𝗲 𝗦𝗰𝗶𝗲𝗻𝗰𝗲𝘀 𝗩𝗲𝗻𝘁𝘂𝗿𝗲 𝗖𝗮𝗽𝗶𝘁𝗮𝗹 𝗠𝗼𝗻𝗶𝘁𝗼𝗿 – 𝗘𝘂𝗿𝗼𝗽𝗲” is now available. 🔍 Read the latest financing trends in venture capital in the European life science industry. Our monitor covers Biotech, Pharmaceutical, MedTech, and HealthTech companies. As of the end of March 2024 we identified the following current VC trends in Europe: - Total Healthcare & Life Sciences funding reached EUR 1,962m - Biotech received 60% of the total investment volume (EUR 1,172m) with oncology being the leading indication (53%) - In March Tubulis GmbH (Germany) secures the highest transaction volume with EUR 128m, followed by Nouscom (Switzerland) with EUR 76m and Mission Therapeutics (United Kingdom) with EUR 51m - M&G Investments (United Kingdom) is the most active investor (by deal volume), followed by Patient Square Capital (United States) and Rock Springs Capital (United States) More here: https://lnkd.in/dappZ5WX
To view or add a comment, sign in
-
-
🌟 Exciting News! 🌟 We are thrilled to share that our CEO & Co-Founder, LakshmiDevi Ethirajan, will be moderating a panel at the 20th BioPharma Nexus Conference in San Diego. The panel discussion will focus on "Advancing Hit Discovery for Complex and Emerging Targets. Join us in San Diego on May 8-9 to gain insights from industry leaders and see how innovations are shaping the future of #DrugDiscovery!
Join us for the 20th BioPharma Drug Discovery Nexus Conference on May 8th-9th at the Sheraton Mission Valley San Diego Hotel! We're delighted to host the panel "Advancing Hit Discovery for Complex and Emerging Targets," where industry experts will share invaluable insights into navigating the intricate landscape of drug discovery. Our esteemed panelists include: - Dr. LakshmiDevi Ethirajan: Co-Founder & CEO at SmaBio Labs. - Phillip Chu: Scientist 3 at Genentech. - Nikhil Jain, Ph.D: Senior Scientist at insitro. - Loiy Ahmed Hassan: Senior Scientist at AstraZeneca. - Mariyam Zuberi: Scientist at Sorrento Therapeutics These panelists collectively embody the spirit of innovation and collaboration essential for advancing hit discovery in today's dynamic landscape. 🔍 We invite you to explore the frontiers of drug discovery with us and chart a course towards transformative therapies. Don't miss out on this pivotal discussion shaping the future of the industry! #NEXUSconference #DrugDiscovery #BioPharmaNexusConference #ProcurementDirect #HitDiscovery #SanDiegoConference
To view or add a comment, sign in
-